Insmed Incorporated (NASDAQ:INSM) Holdings Lifted by Blue Trust Inc.

Blue Trust Inc. grew its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 25.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,462 shares of the biopharmaceutical company’s stock after buying an additional 503 shares during the period. Blue Trust Inc.’s holdings in Insmed were worth $180,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in INSM. Dimensional Fund Advisors LP acquired a new stake in Insmed in the 2nd quarter valued at approximately $810,000. Truist Financial Corp acquired a new position in shares of Insmed during the second quarter valued at $413,000. SG Americas Securities LLC raised its stake in shares of Insmed by 770.4% during the third quarter. SG Americas Securities LLC now owns 21,561 shares of the biopharmaceutical company’s stock valued at $1,574,000 after purchasing an additional 19,084 shares in the last quarter. Park Avenue Securities LLC raised its stake in shares of Insmed by 28.5% during the third quarter. Park Avenue Securities LLC now owns 5,597 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 1,240 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in Insmed by 25.3% in the third quarter. Handelsbanken Fonder AB now owns 43,581 shares of the biopharmaceutical company’s stock worth $3,181,000 after purchasing an additional 8,800 shares during the period.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,912,553.60. This represents a 4.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 195,880 shares of company stock valued at $14,452,494 in the last three months. 4.60% of the stock is currently owned by company insiders.

Insmed Stock Up 4.0 %

Shares of NASDAQ:INSM opened at $81.01 on Wednesday. The firm has a 50 day simple moving average of $72.58 and a 200 day simple moving average of $72.99. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $81.25. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market cap of $14.49 billion, a PE ratio of -14.60 and a beta of 1.11.

Analyst Upgrades and Downgrades

Several research firms have commented on INSM. Bank of America raised their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Truist Financial reissued a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. increased their price target on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.